Abstract
This article examines the response of West German cities to the end of guest worker recruitment in 1973 and to the federal government's implementation of its foreigner policy of ...“consolidation” in the mid-1970s. It argues that cities critiqued federal policies as failing to address the long-term impact of a permanent migrant population and called for a more comprehensive immigration policy that addressed such a population. Fearing potential social problems from a settled foreigner population, cities saw greater social infrastructure investments as essential for the integration of not just individual guest workers but entire foreigner families. By continuing to support the reunification of foreigner families after the end of guest worker recruitment, cities decoupled their assessment of a resident foreigner population from a purely labor market perspective and thought more broadly of the multifaceted impact and demands that the foreigner population made on their communities.
Full text
Available for:
DOBA, IZUM, KILJ, NUK, ODKLJ, PILJ, PNG, SAZU, UILJ, UKNU, UL, UM, UPUK
This article examines the response of West German cities and their main political pressure group, the Deutsche Städtetag (DST, The German Council of Municipalities) to the arrival of guest workers ...between 1960–7. It argues that unlike the federal government, almost all city authorities quickly understood that a portion of the guest workers would remain permanently in West Germany. As a result, the DST and most cities called for some form of guest worker integration already by the early 1960s. Although often expressing humanitarian concern for the guest workers, the cities framed guest worker integration in terms of limiting costs, preserving social order, and maintaining control over the guest workers. In their discussions on guest worker integration, West German cities racialized the guest workers from southern Europe by maintaining a hierarchy of difference with an assumption that the guest workers would never become fully German.
Full text
Available for:
BFBNIB, INZLJ, NMLJ, NUK, OILJ, PNG, SAZU, UKNU, UL, UM, UPUK, ZRSKP
Through an examination of election campaign propaganda and various public relations campaigns, reflecting new electioneering techniques borrowed from the United States, this work explores how ...conservative political and economic groups sought to construct and sell a political meaning of the Social Market Economy and the Economic Miracle in West Germany during the 1950s.The political meaning of economics contributed to conservative electoral success, constructed a new belief in the free market economy within West German society, and provided legitimacy and political stability for the new Federal Republic of Germany.
This paper explores the role that cultural centres played in the integration of guest workers into the city of Stuttgart, Germany. It argues that the centres were initially used as instruments of ...social control, but after the mid-1960s, as local authorities increasingly envisioned the guest workers as a permanent part of West German society, the focus of the centres was on the integration of guest workers, particularly the 'second generation', into not just the economic, but also the social and civic life of Stuttgart and to further cultural understanding between them and West Germans. Furthermore, the paper shows that the centres acted as spaces in which the guest workers themselves could advance their own interests within Stuttgart and many times were sites where they acted out ethnic and political conflicts from their homelands.
Full text
Available for:
BFBNIB, NUK, PILJ, SAZU, UL, UM, UPUK
This article examines the development of city policy towards guest workers in the city of Stuttgart between 1955 and 1973. It argues that local-level institutional leaders almost immediately ...recognized the social impact of labour migration into the city. Initially Stuttgart officials emphasized the construction of guest-worker cultural centres that would take the guest workers out of public spaces and minimize their potential to create social disruption. However, by the mid-1960s, officials from the city administration and relief organizations realized that the foreign workers were not temporary and therefore began to pursue polices to integrate them into West German society-particularly in terms of providing proper family housing and schooling for guest-worker children. By the late 1960s and early 1970s the city administration began instituting various programmes to encourage more active civic engagement by the guest workers, now termed `foreign co-citizens', through the creation of a Foreigner Advisory Committee and a model integration programme in a city quarter with a high density of foreigners. However, their efforts were significantly hampered because of the larger framework of federal and state policies that continued to treat the quest-worker presence as temporary, left guest workers uncertain about the duration of their residency in West Germany, and offered no long-term path to citizenship for guest workers. Reprinted by permission of Arnold Publishing
Full text
Available for:
DOBA, IZUM, KILJ, NUK, PILJ, PNG, SAZU, SIK, UILJ, UKNU, UL, UM, UPUK
Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary ...analysis of CASTOR, a phase 3 study in relapsed and/or refractory multiple myeloma. A post hoc analysis based on treatment history and longer follow-up is presented. After 19.4 (range: 0 to 27.7) months of median follow-up, daratumumab plus bortezomib and dexamethasone prolonged progression-free survival (median: 16.7 versus 7.1 months; hazard ratio, 0.31; 95% confidence interval, 0.24-0.39; P <0.0001) and improved the overall response rate (83.8% versus 63.2%; P <0.0001) compared with bortezomib and dexamethasone alone. The progression-free survival benefit of daratumumab plus bortezomib and dexamethasone was most apparent in patients with 1 prior line of therapy (median: not reached versus 7.9 months; hazard ratio, 0.19; 95% confidence interval, 0.12-0.29; P <0.0001). Daratumumab plus bortezomib and dexamethasone was also superior to bortezomib and dexamethasone alone in subgroups based on prior treatment exposure (bortezomib, thalidomide, or lenalidomide), lenalidomide-refractory status, time since last therapy (≤12, >12, ≤6, or >6 months), or cytogenetic risk. Minimal residual disease-negative rates were >2.5-fold higher with daratumumab across subgroups. The safety profile of daratumumab plus bortezomib and dexamethasone remained consistent with longer follow-up. Daratumumab plus bortezomib and dexamethasone demonstrated significant clinical activity across clinically relevant subgroups and provided the greatest benefit to patients treated at first relapse.
clinicaltrials.gov identifier: NCT02136134.
The Rise of Nazism Mark E. Spicka
Understanding and Teaching the Holocaust,
07/2020
Book Chapter
The question of why by January 1933 Adolf Hitler and the Nazi Party were able to rise to power from relative obscurity is crucial to understanding the origins and perpetration of the Holocaust. ...Although many Holocaust educators understandably focus their attention on the period of 1933 to 1945, an examination of Nazi electoral success and the demise of the Weimar Republic reveals how the Holocaust was part of a larger process whose outcomes were not preordained. The period of 1918 to 1933 illustrates quite distinctly how a racist, extremist political movement came to power, destroying a democracy, and how social
IgM myeloma is a rare hematologic malignancy for which the clinicopathological features and patient outcomes have not been extensively studied. We carried out a multicenter retrospective study in ...patients with diagnosis of IgM myeloma defined by >10% marrow involvement by monoclonal plasma cells, presence of an IgM monoclonal paraproteinemia of any size, and anemia, renal dysfunction, hypercalcemia, lytic lesions and/or t(11;14) identified by FISH. A total of 134 patients from 20 centers were included in this analysis. The median age at diagnosis was 65.5 years with a male predominance (68%). Anemia, renal dysfunction, elevated calcium and skeletal lytic lesions were found in 37, 43, 19, and 70%, respectively. The median serum IgM level was 2,895 mg dL−1 with 19% of patients presenting with levels >6,000 mg dL−1. International Staging System (ISS) stages 1, 2, and 3 were seen in 40 (33%), 54 (44%), and 29 (24%) of patients, respectively. The malignant cells expressed CD20 (58%) and cyclin D1 (67%), and t(11;14) was the most common cytogenetic finding (39%). The median overall survival (OS) was 61 months. Higher ISS score was associated with worse survival (P = 0.02). Patients with IgM myeloma present with similar characteristics and outcomes as patients with more common myeloma subtypes.
Full text
Available for:
BFBNIB, FZAB, GIS, IJS, KILJ, NLZOH, NUK, OILJ, SAZU, SBCE, SBMB, UL, UM, UPUK
Perhaps the most remarkable development in the Federal Republicof Germany since World War II has been the creation of its stabledemocracy. Already by the second half of the 1950s, political ...commentatorsproclaimed that “Bonn is not Weimar.” Whereas theWeimar Republic faced the proliferation of splinter parties, the riseof extremist parties, and the fragmentation of support for liberal andconservative parties—conditions that led to its ultimate collapse—theFederal Republic witnessed the blossoming of moderate, broadbasedparties.1 By the end of the 1950s the Christian DemocraticUnion/Christian Social Union (CDU), Social Democratic Party(SPD) and Free Democratic Party (FDP) had formed the basis of astable party system that would continue through the 1980s.
Full text
Available for:
DOBA, IZUM, KILJ, NUK, ODKLJ, PILJ, PNG, SAZU, UILJ, UKNU, UL, UM, UPUK
Introduction: IgM-secreting myeloma is rare, encompassing about 1% of all the myeloma cases. Given its rarity, the characteristics and survival of these patients have not been extensively studied. ...Therefore, we carried out a multicenter retrospective study in patients with IgM myeloma.
Methods: The study protocol was reviewed and approved by the Institutional Review Board of each participating institution. Clinical data were gathered and included age, sex, hemoglobin, calcium, LDH, estimated glomerular filtration rate (GFR), presence of lytic bone lesions, International Staging System score, cytogenetic abnormalities, final outcome and overall survival (OS) time. OS was defined as the time in months from diagnosis to last follow-up or death. The Chi-square and the rank-sum tests were used to compare categorical and continuous variables, respectively. The Kaplan-Meier method was used to estimate OS and the log-rank waas used to compare groups. The Cox proportional-hazard regression method was used to fit univariate and multivariate survival models, reported as hazard ratio (HR) with 95% confidence intervals (CI). All reported p-values are two-sided, and were considered significant if less than 0.05.
Results: A total of 159 patients with IgM myeloma from 20 centers from Europe, USA and Latin America were included in this analysis. Patients were diagnosed between 1996 and 2015. The median age at diagnosis was 65 years (range 37-86 years) with a male predominance (68%). The median serum IgM level was 2510 mg/dl (range 27-12,100 mg/dl) with 25% of patients having a serum IgM within normal limits but an IgM monoclonal spike detectable in serum electrophoresis. Hemoglobin levels <10 g/dl were seen in 49 patients (32%), serum calcium was elevated in 24 (16%), estimated GFR of 60 ml/min or less in 56 (37%), lytic lesions were detected in 86 (58%), and serum LDH was elevated in 28 (24%). ISS scores of 1, 2 and 3 were seen in 53 (36%), 63 (43%) and 31 (21%) of patients, respectively. Although immunohistochemistry and/or flow cytometry data were limited, CD20 expression was seen in 15/26 (58%) and cyclin D1 in 10/15 (67%) patients. The most common cytogenetic abnormalities were t(11;14) in 26/67 (39%), del13q in 25/76 (33%) and del17p in 6/76 (8%) patients. 149 patients (94%) received at least one line of systemic therapy for myeloma of which 13 (9%) received rituximab as part of initial therapy. After a median follow-up of 47 months, 74 patients (47%) have died. The median OS was 62 months (95% CI 51-79 months). Cause of death was known in 38 patients, and the most common was myeloma progression (74%). IN the univariate analysis, prognostic factors associated with a worse OS were age (HR 1.03, 95% CI 1.01-1.06; p=0.01) and ISS score (ISS 2: HR 1.43, 95% CI 0.83-2.48; p=0.2, and ISS 3: HR 3.03, 95% CI 1.54-5.98; p=0.001, using ISS 1 as reference group), while male sex was associated with a better OS (HR 0.56, 95% CI 0.34-0.90; p=0.02). Hemoglobin, calcium, estimated GFR and lytic lesions were not associated with OS. In the multivariate analysis, male sex was associated with a better OS (HR 0.57, 95% CI 0.35-0.95; p=0.03) and ISS with worse OS (ISS 2: HR 1.57, 95% CI 0.89-2.74; p=0.12, and ISS 3: HR 2.76, 95% CI 1.38-5.55; p=0.004, using ISS 1 as reference group).
Conclusion: Patients with IgM myeloma apparently present with similar clinical characteristics as patients with non-IgM myeloma. Pathologically, CD20 and cyclin D1 expression is common. The most common cytogenetic abnormalities identified were t(11;14) and del13q. Survival does not appear shorter than non-IgM myeloma patients, and the ISS appears to have similar prognostic value.
Castillo:Millennium: Research Funding; Janssen: Honoraria; Otsuka: Consultancy; Biogen: Consultancy; Abbvie: Research Funding; Pharmacyclics: Honoraria. Ghobrial:Celgene: Honoraria, Research Funding; BMS: Honoraria, Research Funding; Novartis: Honoraria; Takeda: Honoraria; Noxxon: Honoraria; Amgen: Honoraria. Hájek:Celgene: Consultancy, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Janssen: Honoraria; BMS: Honoraria; Takeda: Consultancy. Hungria:International Myeloma Foundation Latin America: Membership on an entity’s Board of Directors or advisory committees; Takeda: Consultancy; Amgen: Consultancy; Roche: Consultancy; Bristol: Consultancy; Janssen: Consultancy, Speakers Bureau. Niesvizky:Celgene: Consultancy, Research Funding, Speakers Bureau; Takeda: Consultancy, Research Funding, Speakers Bureau; Onyx: Consultancy, Research Funding, Speakers Bureau. Reagan:Alexion: Honoraria; Seattle Genetics: Membership on an entity’s Board of Directors or advisory committees. Richardson:Celgene: Membership on an entity’s Board of Directors or advisory committees. Spicka:Janssen Cilag: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Honoraria; BMS: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Millenium: Honoraria. Gertz:Celgene: Honoraria; Med Learning Group: Honoraria, Speakers Bureau; Research to Practice: Honoraria, Speakers Bureau; Alnylam Pharmaceuticals: Research Funding; Novartis: Research Funding; Prothena Therapeutics: Research Funding; Ionis: Research Funding; NCI Frederick: Honoraria; Sandoz Inc: Honoraria; GSK: Honoraria; Annexon Biosciences: Research Funding.
Full text
Available for:
GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP
PDF
